Indeed, in a recent study from our lab [58] we performed a screen using FGFR2-based splicing reporters and have identified small molecules that switch FGFR2 splicing and EMT phenotypes; therefore, modulation of FGFR2 splicing could be a potential cancer therapeutic target. This evidence concerns the gene FGFR2 and cancer.